#### Hospitalisations, 2020-21



AOD-related hospitalisations among Australians aged  $\geq$  50 years have increased over the last two decades.



Approximately three in five hospitalisations occurred among males in 2020-2021.

30%

Unintentional

Three in five overdose

hospitalisations were

intentional.

7%

Undetermined

intent

59%



were most common among those aged 50-59 years.

Antiepileptic, sedative-

Non-opioid analgesics

Amphetamine-type

hypnotic and anti-

parkinsonism drugs

79% Alcohol

Opioids

stimulants

The vast majority of all AOD-

related hospitalisations were

attributable to alcohol.


5%

4%


2%

2%


44%27.1



< 1% of alcohol-related hospitalisations were attributable to overdose in 2020-21, with dependence the leading diagnosis (44%).




Percentage Rate per 100,000 Although the majority of hospitalisations occurred in major cities, the rate was highest in remote and very remote areas.




94% Other principal diagnosis

Few alcohol-related deaths were attributable to overdose in 2021, with cardiovascular, digestive and endocrine diseases the leading diagnosis (71%).




Although the majority of deaths occurred in major cities, the rate per 100,00 people was comparable across remoteness areas.




Two-fifths of other drug hospitalisations were attributable to overdose in 2020-2021.

#### **Deaths**, 2021




AOD-induced deaths among Australians aged  $\geq$  50 years have increased slightly over the past two decades.



The majority of other drugrelated deaths were attributable to overdose.




Approximately two in three deaths were male.




61% Unintentional 34% Intentional 6% Undetermined intent

In 2021, most overdose deaths were unintentional.



Opioids, and antiepileptic, sedative-hypnotic and antiparkinsonism drugs were the most common drug types involved in drug overdose deaths.

#### Treatment, 2021






Treatment episodes among Australians aged  $\geq$  50 years have increased over the past two decades.

68%

Approximately three in five people entering treatment were male.



The rate of people entering treatment for amphetamines has increased 23-fold over the past two decades.





Although the majority of treatment episodes occurred in major cities, the rate per 100,00 people was highest in remote and very remote areas.


#### Use, 2022/23

Alcohol


Opioids

Amphetamines


Cannabinoids









Alcohol was the most common substance that Australians aged  $\geq$  50 years reported using in the past year.




Past year AOD use was comparable among males and females.



Past year cannabis use increased three-fold between 2001 and 2022/23.



Past year AOD use was lowest among those aged  $\geq 80$  years.



30% of Australians aged  $\geq$  50 years reported exceeding Australia's drinking guidelines, with this being highest among those aged 50-69 years.

9%

8%

7%

Alcohol was the most common drug that

people were entering treatment for.

#### Priority groups Men:



Males had higher rates of AOD-induced deaths and AOD-related hospitalisations compared to females, which remained consistent across age-groups and remoteness areas.

Older adults who use opioids

and/or benzodiazepines:

#### People aged 50-59 years:

#### Older adults who use alcohol:



People aged 50-59 years consistently had higher rates of AOD-related harms, compared to those aged ≥60 years.

Older adults who use cannabis:



Alcohol was by the far the most commonly used substance by people aged ≥50 years, with almost one in three exceeding drinking guidelines. The majority of AODrelated hospitalisations and treatment episodes were attributable to alcohol.

# Older adults who use amphetamine-type stimulants:



Opioids and antiepileptic, sedativehypnotic and anti-parkinsonism drugs (e.g., benzodiazepines) were the most common drugs involved in drug overdose deaths.



Past year cannabis use tripled between 2001 and 2022/23, with a five-fold increase in people entering treatment for cannabis.



Substantial increases in hospitalisations, overdose deaths and treatment episodes were observed for amphetamine-type stimulants over the past two decades.

## Risk factors

### Location:



Most harms related to illegal or prescription drugs were largely the result of overdose, and occurred at home.

#### **Remoteness areas:**



Rates of hospitalisations, deaths and treatment episodes were highest in remote and very remote areas.

#### **Polysubstance use:**



In 2021, two-thirds of AODinduced deaths involved >1 drug class, although this was less common in AOD-related hospitalisations.

#### **Psychosocial risk factors:**



Personal history of self-harm was the most common risk factor in both intentional and unintentional.